Abstract
Transitioning a patient with chronic pain from a fentanyl patch to a buprenorphine patch has not been well described in the literature. Even after a patient removes their fentanyl patch, the residual fentanyl in the skin continues to be absorbed for hours. Due to the risk of precipitated withdrawal when initiating buprenorphine, this transition is a more challenging opioid rotation to plan safely. We report a case of a patient who had been using a fentanyl patch for over 10 years and was successfully rotated directly to a buprenorphine patch.
Publisher
Weston Medical Publishing
Reference9 articles.
1. Health Canada: An action plan for pain in Canada. 2021. Available at https://www.canada.ca/content/dam/hc-sc/documents/corporate/about-health-Canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2021-rapport/report-rapport-2021-eng.pdf. Accessed August 1, 2023.
2. HQO Quality Standards: Chronic pain: Care for adults, adolescents, and children. Available at https://www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-chronicpain-quality-standard-en.pdf. Accessed August 1, 2023.
3. Murphy L, Babaei-Rad R, Buna D, et al.: Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions. Can Pharm J. 2018; 151(2): 114-120.
4. Chen KY, Chen L, Mao J: Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014; 120(5): 1262-1274.
5. Jorgenson D, Halpape K: Evaluation of a pharmacist-led interprofessional chronic pain clinic in Canada. Can Pharm J. 2023; 156(5). DOI: 10.1177/17151635231188334.